NxStage Nx2me Connected Health Improves Home Hemodialysis
Zacks Investment Research | Dec 10, 2017 09:21PM ET
NxStage Medical, Inc. (NASDAQ:NXTM) announced that its Nx2me Connected Health (remote patient management system) reduces home hemodialysis technique failure or conversion to in-center hemodialysis by 29%. Notably, Nx2me Connected Health is a telehealth platform for the collection and delivery of home hemodialysis treatment and patient medical information.
The outcome of 606 Nx2me users and contemporary matched controls was compared.. Per management, technique failure was reduced by 34% in patients who began using Nx2me within 3 months after initiating home hemodialysis, compared to matched controls. Moreover, patients who started using Nx2me during home hemodialysis training were 61% more likely to complete the process.
The Nx2me iPad app is an important component of the Nx2me platform. The app has been designed to make home therapy more user-friendly by capturing data and wirelessly sending it to the respective centers after each treatment. The timely receipt of electronic flowsheets from the app enables early intervention, lowering possibilities of complications and even hospitalization. Also, Nx2me has been integrated with center EMR systems to provide treatment and billing information to physicians.
Developments in Dialysis Platform
The company is consistently trying to expand its Dialysis platform. NxStage announced the FDA approval of its System One platform for solo home hemodialysis treatment in August. In the same month, the company announced that its subsidiary NxStage Kidney Care is partnering with Dialyze Direct to support patients in need of on-site skilled-nursing facilities (SNF) for dialysis treatment in Ohio. NxStage will now leverage on its System One platform and Dialyze Direct’s unique model for treating geriatric SNF patients with end stage renal disease (ESRD).
Market Trends Buoy Optimism
Data from Markets and Markets reveal that the global hemodialysis and peritoneal dialysis market is expected to reach a worth of $83.89 billion by 2021, at a CAGR of 6.0%. In view of the solid prospects, NxStage’s efforts to boost its Dialysis unit raise optimism.
NxStage to Get Acquired
In August, German dialysis provider Fresenius Medical Care signed an agreement to acquire all outstanding shares of NxStage for $30 a share. The transaction has been valued at $2 billion and is subject to close by 2018, on approval of NxStage stockholders and other customary conditions (read more: Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.